BusinessElectronics
0
Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy - Vertex Pharmaceuticals Newsroom
Comments